SGMT
Income statement / Annual
Last year (2024), Sagimet Biosciences Inc.'s total revenue was $0.00,
a decrease of 100.00% from the previous year.
In 2024, Sagimet Biosciences Inc.'s net income was -$45.57 M.
See Sagimet Biosciences Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$0.00 |
$2.00 M |
$0.00 |
$0.00 |
$0.00 |
$0.00 |
| Cost of Revenue |
$0.00
|
$0.00
|
$130.00 K
|
$134.00 K
|
$124.00 K
|
$88.00 K
|
| Gross Profit |
$0.00
|
$2.00 M
|
-$130.00 K
|
-$134.00 K
|
-$124.00 K
|
-$88.00 K
|
| Gross Profit Ratio |
0
|
1
|
0
|
0
|
0
|
0
|
| Research and Development Expenses |
$38.44 M
|
$19.78 M
|
$24.92 M
|
$19.34 M
|
$8.18 M
|
$8.39 M
|
| General & Administrative Expenses |
$16.01 M
|
$12.96 M
|
$6.14 M
|
$4.38 M
|
$3.22 M
|
$5.86 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$16.01 M
|
$12.96 M
|
$6.14 M
|
$4.38 M
|
$3.22 M
|
$5.86 M
|
| Other Expenses |
$0.00
|
$0.00
|
$3.00 K
|
$0.00
|
$0.00
|
-$73.00 K
|
| Operating Expenses |
$54.45 M
|
$32.74 M
|
$31.06 M
|
$23.72 M
|
$11.40 M
|
$14.25 M
|
| Cost And Expenses |
$0.00
|
$32.74 M
|
$31.06 M
|
$23.72 M
|
$11.40 M
|
$14.25 M
|
| Interest Income |
$0.00
|
$2.86 M
|
$553.00 K
|
$26.00 K
|
$30.00 K
|
$128.00 K
|
| Interest Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$64.00 K
|
| Depreciation & Amortization |
$0.00
|
$0.00
|
$130.00 K
|
$134.00 K
|
$124.00 K
|
$88.00 K
|
| EBITDA |
-$45.57 M |
-$30.74 M |
-$30.37 M |
-$24.31 M |
-$11.25 M |
-$14.11 M |
| EBITDA Ratio |
0
|
-15.37
|
0
|
0
|
0
|
0
|
| Operating Income Ratio |
0
|
-15.37
|
0
|
0
|
0
|
0
|
| Total Other Income/Expenses Net |
$8.89 M
|
$2.86 M
|
$556.00 K
|
-$723.00 K
|
$30.00 K
|
-$9.00 K
|
| Income Before Tax |
-$45.57 M
|
-$27.88 M
|
-$30.50 M
|
-$24.44 M
|
-$11.37 M
|
-$14.26 M
|
| Income Before Tax Ratio |
0
|
-13.94
|
0
|
0
|
0
|
0
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
-$9.00 K
|
| Net Income |
-$45.57 M
|
-$27.88 M
|
-$30.50 M
|
-$24.44 M
|
-$11.37 M
|
-$14.26 M
|
| Net Income Ratio |
0
|
-13.94
|
0
|
0
|
0
|
0
|
| EPS |
-1.45 |
-1.53 |
-1.38 |
-1.1 |
-0.51 |
-0.64 |
| EPS Diluted |
-1.45 |
-1.53 |
-1.38 |
-1.1 |
-0.51 |
-0.64 |
| Weighted Average Shares Out |
$31.35 M
|
$18.19 M
|
$22.17 M
|
$22.17 M
|
$22.17 M
|
$22.17 M
|
| Weighted Average Shares Out Diluted |
$31.35 M
|
$18.19 M
|
$22.17 M
|
$22.17 M
|
$22.17 M
|
$22.17 M
|
| Link |
|
|
|
|
|
|
